In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Boosted By Alcon, Generic Sales And Gilenya Launch in Second Quarter

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis lifted by strong sales of recently launched products in the second quarter, and by strong growth in its Alcon, generics and consumer health divisions.
Advertisement

Related Content

EU And U.S. Regulators Toughen CV Monitoring Requirements For Novartis's Gilenya
Optimer's Fidaxomicin Among Three NMEs Given Positive Review By Europe's Regulators
Consolidated Alcon Eye Division Has Key Role In Maintaining Novartis’ Growth
Gilenya Off And Running, But Keeping Pace Long-Range Is Key
Novartis' Gilenya: Down But Not Out With NICE
EU's Advisory Panel Clears BMS/Pfizer's Apixaban; Turns Down Vectibix Extension
'Focused Diversification' Will Lead to Above-Average Growth, Says Novartis
Novartis' Gilenya: Efficacy, Patient Assistance Lie At Heart Of Marketing Push
Novartis' Gilenya: Efficacy, Patient Assistance Lie At Heart Of Marketing Push
Galvus Won’t Proceed In U.S. Without More FDA Clarity On Prospects, Novartis Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS072534

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel